NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN) announced today that on July 6, 2007 it received a letter from The NASDAQ Stock Market stating that for the last 30 consecutive business days, the closing bid price per share for AVANT’s common stock has been below the $1.00 minimum per share requirement for continued inclusion under NASDAQ Marketplace Rule 4450(a)(5).
